These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34530381)

  • 21. Orphan drugs and orphan tests in the USA.
    Thoene JG
    Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190
    [No Abstract]   [Full Text] [Related]  

  • 22. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success.
    Saltonstall P; Ross H; Kim PT
    Milbank Q; 2024 Mar; 102(1):83-96. PubMed ID: 38087888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Creating hope" and other incentives for drug development for children.
    Connor E; Cure P
    Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The legal regulation of life cycle of orphan pharmaceuticals].
    Gildeyeva GN; Kartavtsova TV
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do investors value the FDA orphan drug designation?
    Miller KL
    Orphanet J Rare Dis; 2017 Jun; 12(1):114. PubMed ID: 28629392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The challenges of orphan drugs and orphan diseases: real and imagined.
    Hudson I; Breckenridge A
    Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval.
    Harada K; Toriyabe K; Ono S
    J Clin Pharmacol; 2020 Jan; 60(1):117-124. PubMed ID: 31364772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 30. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases.
    Miller KL; Fermaglich LJ; Maynard J
    Orphanet J Rare Dis; 2021 Jun; 16(1):265. PubMed ID: 34107994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
    Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
    Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Traits, trends and hits of orphan drug designations in cystic fibrosis.
    Costa E; Girotti S; van den Ham HA; Cipolli M; van der Ent CK; Taylor-Cousar JL; Leufkens HGM
    J Cyst Fibros; 2023 Sep; 22(5):949-957. PubMed ID: 37507282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Readers Want Reforms of Orphan Drug Act.
    Manag Care; 2017 Jun; 26(6):21. PubMed ID: 28661837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease awareness or subtle product placement? Orphan diseases featured in the television series "House, M.D." - a cross-sectional analysis.
    Mechler K; Rausch J; Mountford WK; Ries M
    BMC Med Ethics; 2020 Mar; 21(1):20. PubMed ID: 32171294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
    Mechler K; Mountford WK; Hoffmann GF; Ries M
    Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA's Office of Orphan Products Development: providing incentives to promote the development of products for rare diseases.
    Patel S; Miller Needleman KI
    J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):387-393. PubMed ID: 31278433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Market incentives and pharmaceutical innovation.
    Yin W
    J Health Econ; 2008 Jul; 27(4):1060-1077. PubMed ID: 18395277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Food and Drug Administration's Office of Orphan Products Development: incentives, grants, and special designations speed therapies for orphan diseases.
    Haffner ME
    Retina; 2005 Dec; 25(8 Suppl):S89-S90. PubMed ID: 16374359
    [No Abstract]   [Full Text] [Related]  

  • 40. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
    Burke KA; Freeman SN; Imoisili MA; Coté TR
    Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.